Axsome Therapeutics (AXSM) has moved back into focus after reporting third quarter 2026 results that showed higher revenue and a smaller net loss, alongside an annualized revenue run rate above US$1b....
Source LinkAxsome Therapeutics (AXSM) has moved back into focus after reporting third quarter 2026 results that showed higher revenue and a smaller net loss, alongside an annualized revenue run rate above US$1b....
Source Link
Comments